JACC: Case Reports (Feb 2020)

Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients

  • Johnny Chahine, MD,
  • Patrick Collier, MD, PhD,
  • Anjli Maroo, MD,
  • W.H. Wilson Tang, MD,
  • Allan L. Klein, MD

Journal volume & issue
Vol. 2, no. 2
pp. 191 – 199

Abstract

Read online

We recount a single-center experience with cardiac immunity-related adverse effects in patients treated with immune checkpoint inhibitors. Of 2,830 patients, 9 patients (0.3%) developed cardiac immunity-related adverse effects (4 cases of cardiomyopathies, 2 of myocarditis, 2 of acute pericarditis, and 1 of large pericardial effusion). Disease profiles, hospital courses, and outcomes are reported. (Level of Difficulty: Advanced.)

Keywords